Quick Answer
Prime Medicine, Inc. reported Net Income Loss of -$201.14 million for the year ending 2025.
- Prime Medicine, Inc. showed a decrease of -2.7% in Net Income Loss from 2024 to 2025.
- This data is from Prime Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$86.66 million | Q2 2021: $616.0 thousand | Q3 2021: -$16.41 million | Q1 2022: -$23.84 million | Q2 2022: -$29.35 million | Q3 2022: -$29.35 million | Q1 2023: -$39.40 million | Q2 2023: -$42.39 million | Q3 2023: -$50.71 million | Q1 2024: -$45.76 million | Q2 2024: -$55.33 million | Q3 2024: -$52.52 million | Q1 2025: -$51.89 million | Q2 2025: -$52.59 million | Q3 2025: -$50.58 million.
- Over the full 6 years of available data (2020 to 2025), Prime Medicine, Inc.'s Net Income Loss has declined by 5,798.6%.
- Historical annual values: Fiscal year 2025: -$201.14 million | Fiscal year 2024: -$195.88 million | Fiscal year 2023: -$198.13 million | Fiscal year 2022: -$121.82 million | Fiscal year 2021: -$165.37 million | Fiscal year 2020: -$3.41 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: